By Stephen Nakrosis

Sanofi (SNY) on Wednesday said the U.S. Food and Drug Administration approved an expanded use for its Soliqua, a treatment for adults with type 2 diabetes.

Sanofi said the new approval allows Soliqua to be prescribed for patients whose diabetes is uncontrolled on oral antidiabetic medicines.

The drug already was approved for use as an add-on to diet and exercise in adults with type 2 diabetes who are uncontrolled on long-acting insulin or lixisenatide, the company said.

The approval was based on data from a clinical trial that showed treatment with Soliqua led to significantly greater reductions in blood sugar levels compared with insulin glargine and lixisenatide.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

February 27, 2019 17:41 ET (22:41 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Sanofi.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Sanofi.